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	 In	this	study,	we	developed	and	validated	different	spectrophotometric	and	chromatographic
methods	 for	 determination	 of	 clotrimazole	 (CLO)	 and	 hydrocortisone	 (HDC)	 in	 their
combined	 dosage	 form.	 The	 developed	 spectrophotometric	 methods	 were	 first	 derivative
spectrophotometry	 (1D)	 by	measuring	 the	 peak	 amplitude	 at	 247.4	 and	 236.2	 nm	 for	 CLO
and	HDC,	respectively,	second	derivative	of	ratio	spectra	(2DD)	at	225.4	nm	for	CLO	and	269
nm	for	HDC,	dual	wavelength	spectrophotometry	(DW)	by	measuring	absorbance	difference
between	225.4	and	264	nm	for	CLO	and	between	228	and	247	nm	 for	HDC	determination,
advanced	 absorbance	 subtraction	 method	 (AAS)	 between	 225.4	 and	 264	 nm	 and	 mean
centering	of	ratio	spectra	(MCR)	spectrophotometric	method	in	the	range	of	232‐265	nm.	On
the	 other	 hand,	 the	 proposed	 chromatographic	 method	 was	 Ultra	 Performance	 Liquid
Chromatography	method	(UPLC)	using	acetonitrile:water	(50:50,	v:v)	as	a	mobile	phase	and
the	 peaks	 were	 detected	 at	 228	 nm.	 All	 these	 methods	 were	 successfully	 applied	 to
determine	the	two	studied	drugs	in	pure	forms;	laboratory	prepared	mixtures	and	combined
dosage	 form.	Methods	validations	were	 carried	out	 regarding	 linearity,	 accuracy,	 precision
and	selectivity.	The	spectrophotometric	methods	exhibited	a	linear	dynamic	range	over	5‐40
and	 5‐45	 µg/mL	 for	 CLO	 and	HDC,	 respectively,	 and	 over	 3‐35	 and	 5‐50	 µg/mL	 for	 UPLC
method.	 Sensitive	 and	 selective	 spectrophotometric	 and	 UPLC	 methods	 for	 the
determination	 of	 clotrimazole	 and	 hydrocortisone	 in	 their	 topical	 formulation	 were
successfully	developed	and	validated.	The	developed	methods	were	statistically	confirmed	to
be	accurate,	precise	and	reproducible.	
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1.	Introduction	
	
Clotrimazole	 is	 chemically	 known	 as,	 1‐(o‐chloro‐α,α‐di	
phenylbenzyl)imidazole	[1],	it	is	an	imidazole	derivative	with	a	
broad	spectrum	antimycotic	activity.	It	inhibits	biosynthesis	of	
the	 sterol	 ergostol;	 an	 important	 component	 of	 fungal	 cell	
membranes.	 Its	action	 leads	to	 increase	 in	membrane	perme‐
ability	 and	 apparent	 disruption	 of	 enzyme	 systems	 bound	 to	
the	membrane	[2‐4].		
Hydrocortisone	 is	 chemically	 known	 as,	 11,17,21‐tri	
hydroxypregnan‐4‐ene‐3,20‐dione	 [1],	 it	 is	 a	 principal	 gluco‐
corticoid	 hormone.	 It	 is	 produced	 by	 the	 adrenal	 cortex	 and	
has	 been	 used	 to	 treat	 skin	 problems	 such	 as	 rashes	 and	
eczema.	 It	 is	 also	 used	 to	 treat	 many	 immune	 and	 allergic	
disorders	 [2‐4].	 The	 combination	 of	 these	 drugs	 is	 indicated	
topically	 for	 the	 treatment	 of	 skin	 infections	 due	 to	
dermatophytes,	moulds	and	other	fungi.	
Surveying	 the	 literature	 reveals	 various	 methods	 for	
determination	 of	 these	 drugs	 separately;	 for	 CLO;	 it	 was	
analyzed	by	titrimetric	[1,5],	spectrophotometric	[6,7],	TLC	[8]	
and	 HPLC	 methods	 [9‐11],	 for	 HDC;	 polarographic	 [12,13],	
spectrophotometric	 [1,14],	 fluorimetric	 [15],	 TLC	 [16],	 HPLC	
[17‐22]	 and	 LC‐MS/MS	 [23‐25]	 methods.	 There	 is	 only	 one	
reported	HPTLC	method	has	been	published	for	simultaneous	
analysis	 of	 CLO	 and	 HDC	 [26].	 The	 aim	 of	 this	 work	 was	 to	
develop	 and	 validate	 novel	 different	 spectrophotometric	 and	
chromatographic	 methods	 for	 the	 determination	 of	 CLO	 and	
HDC	in	raw	materials	and	in	the	topical	cream.	The	suggested	
methods	 are	 simple,	 rapid,	 accurate,	 selective	 and	 less	 time	
consuming	(as	especially	for	UPLC	of	analysis	time	less	than	3	
min)	 compared	 with	 the	 published	 HPTLC	 method.	 The	
proposed	methods	have	been	optimized	and	validated	as	per	
ICH	 guidelines	 [27]	 and	 were	 found	 to	 obey	 the	 acceptance	
criteria.	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
A	 double	 beam	UV‐visible	 spectrophotometer	 (Shimadzu,	
Japan)	model	UV‐1601	PC	with	quartz	cell	of	1	cm	connected	
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to	an	IBM	compatible	PC,	an	HP‐600	inkjet	printer,	and	UV‐PC	
personal	 software	 version	 3.7	 were	 used.	 The	 spectral	
bandwidth	 used	 was	 2	 nm	 and	 wavelength‐scanning	 speed	
was	 2800	 nm/min.	 Sonix	 TV	 SS‐series	 ultrasonicator	 (USA)	
was	 used	 for	 extraction	 of	 drugs	 from	 their	 pharmaceutical	
formulation.	PLS‐Toolbox	for	use	with	MATLAB®	7.1	used	for	
mean	centering	of	ratio	spectra	method.	Dionex	Ultimate	3000	
UPLC	 equipped	 with	 a	 Quaternary	 solvent	 delivery	 pump,	
auto‐sampler	and	diode	array	detector	 (Germany)	were	used	
in	 UPLC	 method.	 The	 output	 signal	 was	 monitored	 and	
processed	 using	 Chromeleon	 software	 version	 7.2.1.5537.	
Digital	 balance	 (Sartorius,	 German)	 and	 Jenway	 3505	 pH	
meter	(Stafford	shine,	UK)	were	used.	
	
2.2.	Reagents	and	chemicals	
	
All	 solvents	were	 of	 HPLC	 grade	 and	 the	 chemicals	 used	
were	 of	 analytical	 grade;	 acetonitrile	 and	 methanol	 (Fisher,	
Loughborough,	 UK),	 hydrochloric	 acid,	 analytical	 grade	 (El‐
Nasr	 Pharmaceutical	 Chemical	 Co.,	 Abu‐Zabaal,	 Cairo,	 Egypt).	
De‐ionized	 water	 (SEDICO	 pharmaceuticals	 Co.,	 6th	 October	
City,	 Egypt).	 Solvents	 and	 chemicals	 used	 for	 UPLC	 were	
filtered	through	0.45	μm	membrane	filters	(Sartorius	Stedium	
Biotec.	GmbH,	Goettingen,	Germany).	
	
2.3.	Standards	
	
Standard	CLO	was	kindly	supplied	by	Alexandria	Company	
for	 Pharmaceuticals	 and	 Chemical	 Industries	 (Alexandria,	
Egypt),	 while	 HDC	 was	 kindly	 donated	 by	 Kahira	
Pharmaceuticals	 and	 Chemical	 Industries	 Company	 (Cairo,	
Egypt).	 Their	 purity	 was	 found	 to	 be	 98.70	 and	 99.25%	 for	
CLO	and	HDC,	respectively,	according	to	the	reported	method	
[26].	
	
2.4.	Samples	
	
Dermatin	Cort®	cream	(Batch	No.	804)	was	manufactured	
by	 PHARCO,	 for	 pharmaceutical	 and	 chemical	 industry	
(Alexandria,	Egypt),	each	gram	of	the	cream	claimed	to	contain	
10	mg	of	CLO	and	10	mg	of	HDC.	
	
2.5.	Preparation	of	standard	solutions	
	
2.5.1.	For	spectrophotometric	methods	
	
Standard	stock	solutions	of	CLO	and	HDC	were	prepared	in	
methanol	in	the	concentration	of	1	mg/mL.	Standard	working	
solutions	of	CLO	and	HDC	were	prepared	in	0.05	N	HCl	in	the	
concentration	of	0.1	mg/mL.	
	
2.5.2.	For	UPLC	method	
	
Standard	stock	solutions	of	CLO	and	HDC	were	prepared	in	
acetonitrile	 in	 the	 concentration	 of	 1	 mg/mL.	 Standard	
working	 solutions	 of	 CLO	 and	 HDC	 were	 prepared	 in	 the	
mobile	 phase	 (acetonitrile	 and	 de‐ionized	 water,	 50:50,	 v:v),	
respectively,	in	the	concentration	of	0.1	mg/mL.	
	
2.6.	Laboratory‐prepared	mixtures	
	
Different	mixtures	 containing	 different	 ratios	 of	 CLO	 and	
HDC	were	 prepared	 from	 their	 respective	working	 solutions	
(0.1	mg/mL)	 into	 series	 of	 10	mL	 volumetric	 flasks	 and	 the	
volume	 was	 completed	 to	 the	 mark	 with	 0.05	 N	 HCl	 for	
spectrophotometric	methods.	
		
2.7.	Pharmaceutical	formulation	
	
The	 content	 of	 three	 Dermatin	 Cort®	 cream	 tubes	 was	
mixed	well.	One	g	of	the	cream	containing	10	mg	each	of	CLO	
and	HDC	was	taken	 into	a	200	mL	beaker.	Methanol	 (30	mL)	
was	added	and	the	cream	was	allowed	to	melt	by	warming	at	
70	°C	 in	a	hot	water	 in	ultrasonicator.	The	melted	cream	was	
left	to	solidify	at	room	temperature.	The	warming	and	cooling	
process	was	repeated	 for	 three	 times.	The	 liquid	portion	was	
transferred	to	a	100	mL	volumetric	flask.	Extract	process	were	
repeated	three	times	(15	mL	×3),	warming	and	cooling	process	
were	 repeated	 while	 liquid	 portions	 were	 collected	 in	 the	
volumetric	 flask.	The	volume	was	 completed	with	 the	proper	
solvent	to	obtain	working	solution	of	0.1	mg/mL	of	either	CLO	
or	HDC.	Then	samples	within	linearity	ranges	were	prepared.	
Standard	addition	technique	had	been	also	carried	out.	
	
2.8.	Procedures	
	
2.8.1.	For	ultra‐performance	liquid	chromatography	
method	
	
2.8.1.1.	Chromatographic	conditions	
	
Chromatographic	separation	was	performed	on	a	Hypersil	
Gold	C18	column	(150	mm	×	4.6	id,	3	µm	particle	size)	and	the	
mobile	 phase	 was	 prepared	 by	 mixing	 acetonitrile:	 water	 in	
the	ratio	of	50:50	(v:v).	The	mobile	phase	was	filtered	through	
0.45	µm	Millipore	membrane	 filters	and	degassed	 for	10	min	
using	ultrasonicator	prior	to	use.	Injection	volume	was	20	μL;	
flow	 rate	was	maintained	 at	1	mL/min	under	pressure	 of	 90	
bars.	UV	detection	of	the	effluent	was	performed	at	228	nm.	
	
2.8.1.2.	Construction	of	calibration	curves	
	
Aliquots	 equivalent	 to	 3‐35	 and	 5‐50	 μg/mL	 of	 CLO	 and	
HDC,	 respectively,	 were	 prepared	 from	 their	 respective	
working	solutions	(0.1	mg/mL)	into	two	separate	series	of	10	
mL	 volumetric	 flasks,	 then	 the	 volume	 was	 completed	 with	
acetonitrile:	 water	 (50:50,	 v:v).	 20	 μL	 of	 each	 concentration	
was	injected	in	triplicates.	The	relative	peak	area	(obtained	by	
dividing	the	integrated	peak	areas	of	each	drug	by	the	area	of	
25	 μg/mL	 of	 its	 corresponding	 solution	 as	 an	 external	
standard)	 was	 used	 to	 construct	 calibration	 curve	 of	 each	
component	from	which	its	regression	equation	was	computed.	
	
2.8.2.	For	spectrophotometric	methods	
	
2.8.2.1.	Spectral	characteristics	of	CLO	and	HDC	
	
Zero	 order	 absorption	 spectra	 of	 20	 μg/mL	 each	 of	 CLO,	
HDC	 and	 their	 laboratory	 mixture	 containing	 equal	 concent‐
rations	 of	 both	drugs	 (each	10	μg/mL)	were	 recorded	 in	 the	
UV	range	of	200‐400	nm	using	0.05	N	HCl	as	a	solvent.	
	
2.8.2.2.	Construction	of	calibration	curves	
	
Accurately	 measured	 aliquots	 equivalent	 to	 50‐400	 and	
50‐450	 μg	 of	 CLO	 and	 HDC,	 respectively,	 were	 transferred	
from	 their	working	 solutions	 (0.1	mg/mL)	 into	 two	 series	 of	
10	mL	volumetric	flasks.	The	volume	was	completed	with	0.05	
N	HCl.	
	
2.8.2.3.	First	derivative	spectrophotometric	method	
	
1D	 curves	 were	 recorded	 using	 Δλ	 =	 4	 nm	 and	 scaling	
factor	 =	 10.	 The	 peak	 amplitudes	 at	 247.4	 and	 236.2	 nm	 for	
CLO	 and	HDC,	 respectively,	were	 recorded,	 and	 then	 calibre‐
tion	graphs	were	constructed.	The	regression	equations	were	
then	computed	for	the	studied	drugs.	
	
2.8.2.4.	Second	derivative	of	ratio	spectra	
spectrophotometric	method	
	
2DD	spectra	of	CLO	were	obtained	using	10	μg/mL	of	HDC	
as	a	divisor,	Δλ	=	8	nm	and	scaling	 factor	=	10	while	 the	2DD	
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spectra	of	HDC	were	obtained	using	standard	spectrum	of	10	
μg/mL	CLO	as	a	divisor,	Δλ	=	8	nm	and	scaling	factor	=	10.	2DD	
peak	amplitudes	were	measured	at	225.4	and	269	nm	CLO	and	
HDC,	 respectively.	 The	 calibration	 curves	 were	 constructed	
relating	 the	 peak	 amplitudes	 against	 the	 corresponding	
concentrations	and	the	regression	equations	were	calculated.	
	
2.8.2.5.	Dual	wavelength	method	
	
For	determination	of	CLO,	a	calibration	curve	was	plotted	
relating	the	absorbance	difference	between	225.4	and	264	nm	
against	 its	 corresponding	 concentrations	 and	 the	 regression	
equation	was	computed.	Similarly,	HDC	was	determined	using	
the	 absorbance	difference	 between	228	 and	 247	nm	 and	 the	
corresponding	regression	equation	was	calculated.	
	
2.8.2.6.	Advanced	absorbance	subtraction	method	
	
The	absorbance	of	scanned	spectra	of	CLO	in	the	range	of	
5‐40	μg/mL	was	measured	at	225.4	(isoabsorptive	point,	iso)	
and	 264	 nm.	 Calibration	 graph	 was	 constructed	 relating	 its	
absorbance	 at	 the	 isoabsorptive	point	 (225.4	nm)	 versus	 the	
corresponding	 concentrations	 of	 CLO	 and	 the	 regression	
equation	was	formulated.	Additionally,	a	line	representing	the	
relation	between	 the	absorbance	difference	at	225.4	and	264	
nm	against	 the	absorbance	at	 isoabsorptive	point	(225.4	nm)	
was	plotted,	and	then	the	regression	equation	was	formulated.	
	
2.8.2.7.	Mean	centering	of	ratio	spectra	method	
	
The	absorption	spectra	of	the	prepared	solutions	of	CLO	in	
the	concentration	 range	of	5‐40	μg/mL	were	 recorded	 in	 the	
range	of	232‐265	nm	then	divided	by	the	standard	spectrum	of	
20	μg/mL	of	HDC	the	obtained	ratio	spectra	were	then	mean	
centered.	By	 the	 same	way	 the	 absorption	 spectra	 of	HDC	 in	
the	concentration	 range	of	5‐45	μg/mL	were	 recorded	 in	 the	
range	of	232‐265	nm,	were	divided	by	the	standard	spectrum	
of	20	μg/mL	of	CLO	and	then	the	obtained	ratio	spectra	were	
mean	 centered.	 Calibration	 curves	 of	 the	 developed	 drugs	
were	 constructed	 by	 plotting	 amplitude	 values	 between	 236	
and	254	nm	(peak	to	peak)	for	CLO	and	the	amplitude	values	
between	247	and	264	nm	(peak	to	peak)	for	HDC	against	their	
corresponding	concentrations.	
	
2.8.2.8.	Analysis	of	laboratory	prepared	mixtures	
	
The	 procedure	 given	 under	 construction	 of	 calibration	
curves	 has	 been	 followed	 using	 the	 previously	 prepared	
mixtures.	Concentrations	of	CLO	and	HDC	were	then	calculated	
by	 the	 aid	 of	 the	 corresponding	 computed	 regression	
equations.	
	
2.9.	Application	of	the	methods	to	pharmaceutical	
formulation	
	
The	 procedure	 under	 construction	 of	 calibration	 graphs	
was	 followed	 using	 the	 previously	 prepared	 samples	 of	
Dermatin	Cort®	cream.	Concentrations	of	CLO	and	HDC	were	
calculated	from	their	respective	regression	equations	and	the	
percentage	recoveries	were	then	calculated.	
	
3.	Results	and	discussion	
	
Clotrimazole	and	hydrocortisone	act	as	antimycotic	drugs	
which	indicated	for	the	treatment	of	many	skin	infections	and	
co‐existing	symptoms	of	inflammation.	So,	it	is	very	important	
to	develop	new	analytical	methods	which	are	accurate,	precise	
and	 rapid	 for	 determination	 of	 studied	 drugs	 in	 their	
pharmaceutical	 formulation	 without	 preliminary	 separation.	
The	main	problem	 in	 the	spectrophotometric	analysis	of	CLO	
and	HDC	binary	mixture	was	 the	 spectral	 overlap	of	 the	 two	
proposed	drugs	which	hindered	their	direct	determination.	To	
overcome	 this	 problem,	 we	 established	 different	 spectro‐
photometric	 methods	 which	 are	 money	 and	 time	 saving,	 in	
addition	to	the	more	rapid	chromatographic	one	(UPLC)	which	
is	characterized	by	its	short	analysis	time,	high	selectivity	and	
precision.	
	
3.1.	Methods	optimization	
	
Methods	were	optimized	to	develop	quantitative	methods	
with	those	offer	high	resolution	between	the	drugs	 in	a	short	
time	 of	 analysis.	 It	 was	 necessary	 to	 check	 the	 effect	 of	
different	 parameters	 affecting	methods	 selectivity,	 sensitivity	
and	efficiency.	
	
3.1.1.	For	spectrophotometric	methods	
	
Parameters	 affecting	 resolution	 between	 CLO	 and	 HDC	
were	studied	and	optimized.	These	parameters	are	solvent	and	
divisor	concentration.	
	
3.1.1.1.	Solvent	
	
Different	 solvents	were	 tested	 to	 choose	 the	 suitable	 one	
(Methanol,	 ethanol,	 de‐ionized	water,	 0.05	N	HCl	 and	 0.05	N	
NaOH).	It	was	found	that	0.05	N	HCl	was	the	best	solvent.	
	
3.1.1.2.	Divisor	concentration	
	
The	analytical	parameters	such	as	intercept,	slope	and	the	
correlation	 coefficient	 of	 calibration	 equation	 are	 affected	 by	
the	divisor	 concentration,	 so	 it	was	 tested.	Different	 concent‐
rations	of	CLO	and	HDC	were	tested	as	divisors	(10,	15,	25	and	
30	μg/mL).	It	was	found	that	10	μg/mL	was	the	best	concent‐
ration	for	a	2DD	method	and	20	μg/mL	was	the	most	suitable	
one	for	MCR	method.	
	
3.1.2.	For	UPLC	method	
	
3.1.2.1.	Mobile	phase	
	
Different	 mobile	 phases	 with	 different	 compositions	 and	
ratios	were	tested	to	get	the	best	chromatographic	separation.	
First	 trial	 began	 with	 water:	 methanol	 in	 different	 ratios.	
Asymmetric	 tailed	and	forked	peaks	have	been	obtained.	The	
second	trial	was	to	test	the	effect	of	addition	of	different	ratios	
of	either	 acetic	acid	or	 triethylamine,	but	no	 improvement	 in	
separation	 was	 observed.	 The	 last	 trial	 was	 to	 replace	
methanol	with	acetonitrile	that	 led	to	 improving	 in	the	shape	
of	the	peaks	and	hence	the	resolution	between	them.	Different	
ratios	 of	 water:	 acetonitrile	 were	 tried.	 Finally,	 the	 best	
separation	was	achieved	by	using	a	mobile	phase	consisted	of	
acetonitrile:	water	(50:50,	v:v)	with	a	flow	rate	of	1	mL/min	on	
a	C18	column.	
	
3.1.2.2.	Scanning	wavelength	
	
Different	scanning	wavelengths	were	tested	like	(205,	210,	
228	and	254	nm)	to	choose	the	most	sensitive	wavelength.	The	
wavelength	 228	 nm	 gave	 a	 good	 sensitivity	 for	 all	 the	
components.	 Finally,	 good	 resolution	 and	 acceptable	 peak	
shape	have	resulted	where	 the	 tree	of	HDC	was	1.853	and	of	
CLO	was	2.087,	as	in	Figure	1.	
	
3.2.	Application	of	the	methods	
	
3.2.1.	First	derivative	spectrophotometric	method	
	
The	 zero	 order	 absorption	 spectra	 of	 CLO	 and	 HDC	
displayed	severe	overlapping,	as	shown	in	Figure	2.		
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Table	1.	Regression	and	analytical	parameters	of	the	proposed	methods	for	the	determination	of	clotrimazole	and	hydrocortisone.	
UPLC	MCR AAS	DW	2DD 1D Methods	
HDC CLO HDC CLO HDC CLO HDC CLO HDC CLO HDC CLO Parameters	
5‐50 
	
3‐35	
 
5‐45	
 
5‐40
 
5‐45
	
5‐40 5‐45
	
5‐40
 
5‐45
	
5‐40	
 
5‐45	
 
5‐40	Calibration		
range	(μg/mL) 
0.0376	0.0366 0.0427	0.0081	0.0192	0.0190	0.0179	0.0106	0.0301	0.0221	0.0131	0.0057	Slope 
0.0509	 0.0881	0.2139	0.0127	0.0052	0.0344	0.0419 0.0129	0.1454	0.0009	0.0047	0.0022	Intercept 
0.9999	0.9998	0.9999	0.9999 0.9999	0.9999	0.9998	0.9999	0.9999	0.9999 0.9999	0.9999	Correlation	
coefficient	(r) 
100.13
±0.760	
99.95 
±1.170 
100.08	
±0.830	
99.75
±0.750	
100.12
±0.720	
99.79
±0.610	
99.60
±0.840	
99.68
±0.910	
100.17
±1.060	
99.95	
±0.560	
99.87	
±1.070	
99.21	
±0.670	
Accuracy,	Mean	
±RSD%	
0.001
 
0.003 
 
0.001 0.0080.0070.013 0.0140.0160.0040.006	0.014	0.005	Repeatability	
(RSD%)	1,2 
0.003 
 
0.821 
 
0.006	0.0110.012
	
0.0150.020
	
0.0900.0090.015	0.018	0.007	Intermediate	
Precision	(RSD%)	2	
1.04	0.70 1.18	1.43	1.44	1.39	1.14	1.56	1.38	1.13	1.26	1.21	LOD	(μg/mL)	3	
3.14	2.13 3.58	4.32	4.37	4.21	3.46	4.72	4.19	3.44	3.81	3.65	LOQ	(μg/mL)	4		
1	(RSD%)	of	3	concentrations	(10,	15,	25	μg/mL)	of	each	component	(CLO	and	HDC)	on	the	same	day.	
2	(RSD%)	of	3	concentrations	(10,	15,	25	μg/mL)	of	each	component	(CLO	and	HDC)	on	three	successive	days.	
3	LOD	=	3.3*SD/Slope.		
4	LOQ	=	10*SD/Slope.	
	
	
	
	
Figure	1.	UPLC	chromatogram	of	a	mixture	of	 (A)	HDC	and	(B)	CLO	using	
acetonitrile:	water	(50:50,	v:v)	as	a	mobile	phase	with	UV	detection	at	228	
nm.	
	
	
Figure	2.	Zero	order	absorption	 spectra	of	20	μg/mL	each	CLO	(),	HDC				
(‐‐‐)	 and	 the	 binary	 mixture	 of	 CLO	 and	 HDC	 containing	 10	 μg/mL	 each	
(··)	using	0.05	N	HCl	as	a	solvent.	
	
This	 overlapping	 restricted	 the	 direct	 determination	 of	
studied	 drugs.	 Derivative	 spectrophotometry	 is	 an	 analytical	
method	 of	 great	 utility	 for	 resolving	 the	 overlapped	 spectra	
[28].	 The	 application	 of	 1D	 method	 provided	 a	 selective	
determination	 of	 CLO	 and	 HDC	 by	 measuring	 the	 peak	
amplitude	 at	 247.4	 and	 236.2	 nm,	 respectively,	 as	 shown	 in	
Figure	 3.	 The	 calibration	 curves	 were	 constructed	 and	 the	
regression	equations	were	given	in	Table	1.	
	
3.2.2.	Second	derivative	of	ratio	spectra	spectrophotometric	
method	
	
Another	 method	 for	 resolving	 binary	 mixtures	 without	
prior	separation	is	the	second	derivative	of	the	ratio	spectrum	
spectrophotometric	method	(2DD)	[29].	The	main	advantage	of	
the	 method	 is	 that	 the	 whole	 spectrum	 of	 an	 interfering	
substance	is	canceled.	Accordingly,	the	choice	of	the	selected	is	
not	 critical	 as	 in	 the	 derivative	 spectrophotometric	methods.	
Dividing	 the	 absorption	 spectra	 of	 HDC	 by	 the	 standard	
spectrum	 of	 10	 μg/mL	of	 the	 CLO	 as	 a	 divisor;	 the	 obtained	
ratio	spectra	was	subjected	to	the	second	derivatization	using	
Δλ	=	8	nm	and	scaling	factor	=	10	as	shown	in	Figure	4.	On	the	
other	hands	the	absorption	spectra	of	CLO	were	divided	by	10	
μg/mL	of	HDC	as	a	divisor,	then	the	second	derivative	for	the	
obtained	 spectra	 was	 recorded	 using	 Δλ	 =	 8	 nm	 and	 scaling	
factor	 =	 10,	 Figure	 5.	 The	 peak	 amplitudes	 of	 the	 second	
derivative	of	 ratio	spectra	at	225.4	and	269	nm	were	plotted	
versus	 the	 concentrations	 of	 CLO	 and	HDC,	 respectively.	 2DD	
values	 showed	 good	 linearity	 and	 reproducibility	 at	 these	
wavelengths,	 regression	parameters	were	presented	 in	Table	
1.	
	
	
Figure	3.	First	derivative	absorption	spectra	of	20	μg/mL	each	of	CLO	()	
&	HDC	(‐‐‐)	using	0.05	N	HCl	as	a	solvent.	
	
	
Figure	4.	Second	derivative	of	ratio	spectra	of	20	μg/mL	each	CLO	()	and	
20	μg/mL	of	HDC	(‐‐‐)	using	10	μg/mL	of	CLO	as	a	divisor	and	0.05	N	HCl	as	
a	solvent.
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Figure	5.	Second	derivative	of	 ratio	spectra	of	20	μg/mL	each	of	CLO	()	
and	HDC	(‐‐‐)	using	10	μg/mL	of	HDC	as	divisor	and	0.05	N	HCl	as	a	solvent.	
	
3.2.3.	Dual	wavelength	analysis	method	
	
Different	 wavelengths	 were	 tried	 to	 develop	 a	 dual‐
wavelength	method,	the	best	results	regarding	sensitivity	and	
selectivity	were	 obtained	 by	 using	 the	 absorbance	 difference	
between	225.4	and	264	nm	for	CLO	(where	HDC	has	the	same	
absorbance),	 228	 and	 247	 nm	 for	HDC	 (where	 CLO	has	 zero	
difference)	 as	 shown	 in	Figure	2.	Calibration	graphs	 for	both	
drugs	 were	 constructed	 by	 plotting	 the	 difference	 in	 absor‐
bance	values	at	the	chosen	wavelengths	for	each	drug	against	
their	corresponding	concentrations.	CLO	and	HDC	obeyed	Beer	
Lambert’s	 law	 in	 the	 concentration	 ranges	 of	 5‐40	 and	 5–45	
μg/mL	 for	 CLO	 and	HDC,	 respectively,	with	 good	 correlation	
coefficients	as	in	Table	1.	
	
3.2.4.	Advanced	absorbance	subtraction	method	
	
The	 absorption	 spectra	 of	 the	 standard	 solutions	 of	 CLO	
with	different	concentrations	were	recorded	in	the	wavelength	
range	 of	 200‐400	 nm.	 Two	wavelengths	were	 selected	 225.4	
and	 264	 nm	 where	 HDC	 showed	 equal	 absorbance	 at	 the	
selected	wavelengths	 Figure	 2.	 So	 the	 absorbance	 difference	
∆A	 (Aiso‐A264)	 between	 the	 two	 selected	 wavelengths	 on	 the	
mixture	spectra	is	directly	proportional	to	the	concentration	of	
CLO;	 [30,31].	 A	 calibration	 graph	 was	 plotted	 for	 CLO	
representing	 the	 relationship	 between	 the	 absorbance	
difference	(Aiso‐A264)	against	Aiso	and	the	 following	regression	
equation	was	formulated:	
	
∆A	(Aiso‐A264)	=	0.5115	Aiso	+	0.003			r	=	0.9999	 	 (1)	
	
where	∆A	 is	 the	absorbance	difference	between	 two	 selected	
wavelengths	 for	 CLO	 spectra,	 Aiso	 is	 the	 absorbance	 at	 225.4	
(iso)	 of	CLO.	By	 substituting	using	 the	absorbance	difference	
∆A	 (Aiso‐A264)	 between	 the	 two	 selected	 wavelengths	 of	 the	
mixture	 spectrum	 in	 the	 previous	 equation,	 the	 postulated	
absorbance	 A	 corresponding	 to	 CLO	 at	 Aiso	 was	 obtained.	
Subtracting	 the	 obtained	 absorbance	 of	 CLO	 at	 Aiso	 from	 the	
practically	 recorded	 absorbance	 [ARecorded]	 at	 Aiso	 to	 get	 that	
corresponding	to	HDC	as:	
	
ARecorded	=	AHDC	+	ACLO	 	 	 	 (2)	
	
By	plotting	the	absorbance	of	zero	order	spectra	of	CLO	or	
HDC	 at	 Aiso	 225.4	 nm	 against	 the	 corresponding	 concent‐
rations,	a	unified	regression	equation	was	calculated	and	was	
used	 for	 determination	 of	 both	 CLO	 and	 HDC	 using	 the	
calculated	absorbance	value	of	each	at	iso.	
	
3.2.5.	Mean	centering	of	ratio	spectra	method	
	
The	 developed	 MCR	 method	 is	 based	 on	 the	 mean	
centering	of	ratio	spectra;	it	gets	rid	of	the	derivatization	steps	
and	 therefore	 signal‐to‐noise	 ratio	 is	 increased.	 A	 mathema‐
tical	 explanation	 of	 the	 developed	method	was	 illustrated	 by	
Afkhami	 and	Bahram	 [32].	 Since	 the	wavelength	 range	 taken	
has	great	effect	on	the	obtained	mean	centering	ratio	spectra,	
different	wavelength	 ranges	were	 tested	and	 the	best	 results	
were	given	when	using	 the	wavelength	 range	 from	 (232‐265	
nm)	for	both	CLO	and	HDC.	Also,	the	divisor	concentration	was	
selected	with	care	 to	obtain	maximum	selectivity	and	sensiti‐
vity	 and	 the	 best	 results	 were	 obtained	 on	 using	 20	 μg/mL	
each	 of	 studied	 drugs	 as	 divisors.	 The	 absorption	 spectra	 of	
the	 standard	 solutions	 of	 CLO	 with	 different	 concentrations	
were	 recorded	 and	 divided	 by	 the	 standard	 spectrum	 of	 20	
μg/mL	 of	 HDC	 then	 mean	 centering	 of	 the	 resulted	 ratio	
spectra	 has	 been	 obtained,	 Figure	 6.	 By	 the	 same	 way,	
standard	solutions	of	HDC	with	different	concentrations	were	
recorded	and	divided	by	20	μg/mL	CLO.	Then	mean	centering	
of	the	resulted	ratio	spectra	has	been	obtained,	Figure	7.	The	
amplitudes	 of	 the	 obtained	 mean	 centered	 ratio	 spectra	 at	
236‐254	nm	(peak	to	peak)	and	at	247‐264	nm	(peak	to	peak)	
was	recorded	for	both	CLO	and	HDC,	respectively.	Calibration	
graphs	 were	 plotted	 and	 the	 regression	 equations	 were	
calculated	and	given	in	Table	1.	
	
Figure	6.	Mean	centered	of	first	ratio	spectra	of	CLO	(5‐40	μg/mL)	using	20	
μg/mL	of	HDC	as	a	divisor	and	0.05	N	HCl	as	solvent.	
	
	
Figure	7.	Mean	centered	of	first	ratio	spectra	of	HDC	(5‐45	μg/mL)	using	20	
μg/mL	of	CLO	as	a	divisor	and	0.05	N	HCl	as	solvent.	
	
3.2.6.	Ultra‐performance	liquid	chromatography	method	
	
Separation	was	carried	out	at	ambient	room	temperature	
using	 Hypersil	 Gold	 C18	 column	 (150	 mm	 ×	 4.6	 id’s,	 3	 µm	
particle	 sizes)	 using	 a	 mixture	 of	 acetonitrile:	 water	 in	 the	
ratio	of	(50:50,	v:v)	as	a	mobile	phase	with	flow	rate	1	mL/min	
under	 pressure	 of	 90	 bars	 and	UV	 detection	 at	 228	 nm.	 The	
studied	drugs	had	been	separated	where	the	tR	of	HDC	=	1.853	
and	of	CLO	=	2.087	as	shown	in	Figure	1.	
	
3.3.	Method	validation	
	
Methods	 validation	 was	 performed	 with	 respect	 to	 ICH	
guidelines	[27]	like	linearity,	accuracy,	precision,	LOD	and	LOQ	
were	measured	and	the	results	are	given	in	Table	1.	
	
	
	
376	 Fares	et	al.	/	European	Journal	of	Chemistry	8	(4)	(2017)	371‐377	
	
	
Table	2.	Determination	of	CLO	and	HDC	in	laboratory‐prepared	mixtures	by	the	proposed	spectrophotometric	methods.	
%	Recovery	Ratio		
of	CLO:	HDC 
Conc.		
of	CLO:	HDC		
Mix	
No		 MCR AASDW2DD1D 
HDC CLO HDC CLO HDC CLO HDC CLO HDC	CLO	
100.68100.86 101.46 100.3299.50101.9899.5399.24101.76100.35 1:1		10:10		1	
100.21101.05 100.42 102.0899.5099.1099.2098.2197.9498.42 2:1		20:10		2 
101.74101.05 99.79 98.4799.19100.05100.7698.4499.3598.42 1:1		20:20	3	
101.79100.86 101.53 98.17100.76101.9899.07100.05100.8498.60 1:3		10:30 4 
102.47100.86 99.42 98.21101.0399.1599.75100.95101.7798.60 2:5	10:25 5 
101.3198.62 98.89 99.7799.85101.55100.69101.1999.9099.79 5:3	25:15		6 
101.37 
0.82 ±  
100.55 
 0.95± 		
100.25 
 1.08± 		
99.50 
 1.54± 		
99.97 
 0.75± 		
100.64 
 0.75± 		
99.83 
 0.73± 		
99.68 
0.73± 	
100.26 
 1.50± 	
99.03	
±0.83  
Mean±RSD%	 
	
Table	3.	Quantitative	determination	of	CLO	and	HDC	in	Dermatin	Cort®	cream	by	the	proposed	methods	and	application	of	standard	addition	technique.	
Methods	Parameters Drugs 
UPLCMCR	AASDW2DD1D	
10.0010.00	10.00	10.0010.00	10.00	Taken	(μg/mL)	
Cl
ot
ri
m
az
ol
e	
D
er
m
at
in
	C
or
t	®
	c
re
am
	
(b
at
ch
	N
o.
	8
04
) 
97.24±1.3998.85±1.75 96.98±1.8796.79±1.3097.03±0.9899.18±1.43 Found	%±RSD%	1	
8.008.00	8.008.008.008.00	Pure	added	
(μg/mL) 10.00	10.00 10.0010.0010.0010.00 
12.0015.00	15.0015.0015.0015.00	
99.28	100.31 100.77100.23100.1198.69 %	Recovery	 
100.8698.77 99.56100.94100.45100.00 
100.6399.59 99.3699.37100.15100.59 
100.26±0.85	99.56±0.77	99.90±0.77100.18±0.79	100.24±0.1999.76±0.97 Mean±RSD% 
10.0010.00	10.0010.0010.0010.00	Taken	(μg/mL) 
H
yd
ro
co
rt
is
on
e 99.64±0.8898.34±1.84 98.25±1.8597.45±1.2699.09±1.2097.18±1.37 Found	%±RSD%	
1 
8.008.00	8.008.008.008.00	Pure	added	
(μg/mL) 10.00	10.00	10.00	10.00	10.00	10.00 
12.0015.00	15.0015.0015.0015.00	
100.2599.53 100.7299.97100.09 100.75 %	Recovery	 
99.20100.94 99.85100.09100.0099.69 
99.17100.70 100.2499.87100.78100.05 
99.65±0.62	100.39±0.75	100.27±0.44	99.98±0.11	100.29±0.43100.16±0.54 Mean±RSD% 
	1	All	data	are	represented	as	mean±SD;	n	=	6.	
	
Table	4.	Parameters	of	system	suitability	testing	of	the	developed	UPLC	method	for	the	determination	of	CLO	and	HDC.	
Reference	values	[33]CLO HDC Parameters	
For	a	typical 1	symmetric	peak0.93 0.94 Symmetry	factor 
>	23.08 Resolution	(Rs)	
>	1.5 1.92	Selectivity	(α) 
Increases	with	efficiency	of	the	separation8395 14911	Column	efficiency	(N) 
The	smaller	the	value,	the	higher	the	column	efficiency 0.0020.001 HETP	(cm/plate)	1 
	1	HETP:	Height	equivalent	to	theoretical	plates.	
	
3.3.1.	Specificity	
	
The	specificity	of	these	methods	was	achieved	by	analysis	
of	 different	 synthetic	 prepared	 mixtures	 of	 CLO	 and	 HDC	
within	their	linearity	ranges.	Good	results	were	obtained	from	
all	 the	 proposed	 methods	 shown	 in	 Table	 2.	 These	 results	
confirmed	that	both	CLO	and	HDC	did	not	interfere	with	each	
other.	By	applying	the	developed	methods	to	Dermatin	Cort	®	
cream	 good	 percentage	 recoveries	 were	 obtained	 which	
proved	that	excipients	existed	in	cream	did	not	interfere	with	
any	of	separated	drugs	and	ensuring	its	selectivity,	Table	3.	
	
3.3.2.	Robustness	
	
Robustness	 of	 the	 developed	 UPLC	 method	 was	 proved	
when	 we	 tried	 to	 make	 minor	 deliberate	 changes	 in	 some	
parameters	like	changing	in	%	acetonitrile	in	the	mobile	phase	
±2%,	changing	in	scanning	wavelength	±2	nm	and	changing	at	
flow	 rate	 ±0.05	 mL/min.	 By	 calculating	 the	 %	 RSD	 of	 peak	
areas	 for	 each	 of	 the	 studied	 components	 after	 each	 trial,	 it	
was	 found	 to	 be	 0.009	 and	 0.008	 for	 CLO	 and	 HDC,	
respectively	 in	 changing	%	 of	mobile	 phase	 ±2%,	 0.012	 and	
0.018	for	CLO	and	HDC,	respectively	in	changing	the	flow	rate	
±0.05	mL/min.	They	have	been	confirmed	that	changing	in	the	
studied	 parameters	 did	 not	 have	 a	 significant	 or	 dramatic	
effect	on	the	peak	areas.	
	
3.3.3.	System	suitability	
	
Parameters	 including	 resolution	 (Rs)	 and	 selectivity	 (α)	
factors	were	calculated	for	both	CLO	and	HDC	and	were	found	
to	be	>	2	and	1.5,	respectively.	In	addition,	the	peak	symmetry	
factors	 were	 calculated	 for	 the	 two	 components	 and	 nearly	
equal	 1	 [33].	 Other	 parameters	 such	 as	 height	 equivalent	 to	
theoretical	 plates	 and	 the	 number	 of	 theoretical	 plates	were	
calculated,	and	their	values	were	within	the	acceptable	limits,	
Table	4.	
	
3.3.4.	Statistical	analysis	
	
The	results	of	the	developed	methods	for	determination	of	
CLO	and	HDC	were	statistically	compared	with	those	obtained	
by	applying	a	reported	HPTLC	method	[26]	for	Dermatin	Cort	
®	cream	using	Student’s	t‐test	and	variance	ratio	F‐test	at	95%	
confidence	level.	The	calculated	t	and	F	values	were	less	than	
the	 reported	 ones,	 confirming	 that	 there	 is	 no	 significant	
difference	 between	 them	 with	 respect	 to	 accuracy	 and	
precision,	Table	5.	
	
4.	Conclusions	
	
The	developed	methods	have	been	successfully	applied	for	
the	 determination	 of	 CLO	 and	 HDC	 in	 pure	 and	 in	 their	
combined	 formulation,	 they	 were	 found	 to	 be	 simple,	 rapid	
and	accurate	methods.	The	proposed	UPLC	method	had	some	
advantages	 of	 being	 highly	 selective,	 sensitive	 and	 has	 short	
analysis	 time	 (less	 than	 3	 min),	 hence	 lower	 solvent	
consumption	 over	 other	 HPLC	 methods.	 Also,	 the	 proposed	
spectrophotometric	methods	were	 found	 to	 be	 rapid,	 simple,	
accurate	 and	 less	 expensive.	 The	 suggested	 methods	 were	
completely	validated	and	satisfactory	results	were	obtained.		
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Table	5.	Statistical	comparison	of	the	results	obtained	by	the	proposed	methods	and	the	reported	HPTLC	method	for	the	analysis	of	Dermatin	Cort®	cream.	
Reported 
Method	1	[26]	
UPLC MCR	AAS	DW	2DD	1D	Methods 
HDC CLO HDC CLO HDC CLO HDC CLO HDC CLO HDC CLO HDC CLO Parameters	2	
98.2598.7099.64	97.24	98.3498.8598.2596.9897.4596.7999.09	97.03	97.18	98.96	Mean	(%) 
1.240.98	1.88	1.39	1.841.751.851.871.261.301.30	0.99	1.37	1.67	S.D	
66 6 66666666 6 6 6 n	
 1.250 1.374 1.709	1.258	1.635	1.345	1.304	1.184	0.905	0.876	1.008	1.870	Student’s	
t‐test	
(2.228	)	3 
2.298	2.013	2.201	3.190	2.225	3.643	1.032	1.760	1.099	1.021	1.220	2.905	F‐test	
(5.505) 
1	Reported	HPTLC	method	for	determination	of	CLO	and	HDC	using	Toluene:	Propanol:	Ammonia	(13:3:0.1,	v:v:v)	as	developing	system	reflectance/absorbance	
mode	at	226	nm.	
2	All	data	are	represented	as	mean±SD;	n=6.	
3	Figures	between	parentheses	represent	the	corresponding	tabulated	values	of	t	and	F	(p	=	0.05).	
	
	
Recovery	studies	indicated	that	there	was	no	interference	
from	 cream	 additives,	 the	 developed	 methods	 can	 be	 easily	
applied	 to	quality	control	of	 the	studied	drugs.	Moreover,	 the	
obtained	results	confirmed	the	accuracy	and	precision	of	these	
methods.	
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